The Biggest Manufacturing Challenges Facing TIL Developers

While clinical progress continues to generate excitement across the TIL field, manufacturing remains one of the most significant barriers to broader adoption and commercial success.

Unlike many other therapeutic modalities, TIL therapies require the collection, expansion, and preparation of highly individualized cell products. Each manufacturing run introduces variability that can impact timelines, costs, and ultimately patient access.

One major challenge is consistency. Variability in starting material quality can influence expansion rates, potency, and final product characteristics. Understanding how to identify and manage these factors early in development is becoming increasingly important for developers seeking predictable manufacturing outcomes.

Turnaround time also remains a major consideration. Reducing manufacturing timelines may help ensure patients receive treatment more quickly while improving overall operational efficiency. To address this challenge, organizations are exploring automation, closed-system manufacturing technologies, and optimized workflows.

As programs move toward late-stage development and commercialization, scalability becomes equally important. Manufacturing platforms that perform effectively at clinical scale must also support increased demand while maintaining quality and regulatory compliance.

Ultimately, manufacturing excellence is becoming a competitive differentiator. Developers capable of producing high-quality therapies consistently, efficiently, and at scale will be better positioned to maximize the therapeutic and commercial potential of their TIL programs.